Abstract
Purpose :
The determination of the molecular mechanism underlying retinal pathogenesis and visual dysfunction during innate inflammation, and the treatment effect of rapamycin thereon.
Methods :
The endotoxin-induced uveitis and retinitis mouse model was established by injecting lipopolysaccharide. The mice were subsequently treated with rapamycin, a mammalian target of rapamycin (mTor) inhibitor. The rhodopsin mRNA and protein expression level in the retina, and photoreceptor outer segment (OS) length was measured, and visual function was recorded by electroretinography. Inflammatory cytokines, their related molecules, mTor, and LC3 levels were measured by real-time PCR and/or immunoblotting. Leukocyte adhesion during inflammation was analyzed using concanavalin A lectin.
Results :
The post-transcriptional reduction in the visual pigment of rod photoreceptor cells, rhodopsin, OS length, and rod photoreceptor cell dysfunction during inflammation were suppressed by rapamycin. Activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induction of inflammatory cytokines, such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), and the activation of the downstream signaling protein, signal transducer and activator of transcription 3 (STAT3), which reduces rhodopsin in the retina during inflammation, were attenuated by rapamycin. Increased leukocyte adhesion was attenuated by rapamycin. Interestingly, although mTor activation was observed after NF-κB activation, mTor inhibition suppressed NF-κB activation at the early phase, indicating that the basal level of activated mTor was sufficient to activate NF-κB in the retina. In addition, the inhibition of NF-κB suppressed mTor activation, suggesting a positive feedback loop of mTOR and NF-κB during inflammation. The ratio of LC3II to LC3I was not changed by inflammation, but increased by rapamycin.
Conclusions :
Our results propose the potential use of rapamycin as a neuroprotective therapy to suppress local activated mTor levels, related inflammatory molecules, and the subsequent visual dysfunction during retinal inflammation.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.